Foghorn Therapeutics (FHTX) Short-term Investments (2019 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Short-term Investments came in at $1.2 million in Q1 2026, little changed quarter-over-quarter from $1.2 million in Q4 2025.
Foghorn Therapeutics (FHTX) Short-term Investments (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Short-term Investments history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- On a quarterly basis, Short-term Investments changed N/A year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.2 million, changed N/A from the prior year.
- Short-term Investments was little changed at $1.2 million in Q1 2026 per FHTX's latest filing, from $1.2 million in the prior quarter.
- Across five years, Short-term Investments topped out at $1.2 million in Q2 2025 and bottomed at $25000.0 in Q3 2022.
- The 3-year median for Short-term Investments is $1.2 million (2025), against an average of $1.0 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Sep 30, 2022 | 25,000.00 |
| Sep 30, 2020 | 541,000.00 |
| Dec 31, 2019 | 541,000.00 |